Paloma Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Paloma Partners’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-46,055	Closed	-$1.91M	–	2368
2020 Q3	$1.91M	Buy	+46,055	New	+$2.12M	0.05%	404
2017 Q3	–	Sell	-5,600	Closed	-$678K	–	2531
2017 Q2	$678K	Buy	+5,600	New	+$649K	0.01%	1384
2016 Q4	–	Sell	-6,124	Closed	-$1.01M	–	2197
2016 Q3	$1.01M	Buy	+6,124	New	+$965K	0.01%	1016
2015 Q2	–	Sell	-4,249	Closed	-$1.2M	–	1983
2015 Q1	$1.2M	Buy	+4,249	New	+$920K	0.03%	440
2014 Q4	–	Sell	-1,183	Closed	-$280K	–	1424
2014 Q3	$280K	Sell	1,183 -13,021	-92%	-$3.32M	0.01%	740
2014 Q2	$3.36M	Buy	14,204 +13,204	+1,320%	+$3.48M	0.14%	155
2014 Q1	$330K	Buy	+1,000	New	+$337K	0.02%	498

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Paloma Partners's ICPT Position: Q4 2020 in Review

Paloma Partners sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2020, closing a stake of 46,055 shares — an estimated $1.91M sold.

Paloma Partners first reported a position in ICPT in Q1 2014 and held it in 7 quarters. The position peaked at $3.36M in Q2 2014. 175 funds tracked by Wall St. Rank hold ICPT as of Q4 2020.

Paloma Partners reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Paloma Partners sold 46,055 Intercept Pharmaceuticals, Inc. shares in Q4 2020, an estimated $1.91M.
Paloma Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 7 quarters.
Paloma Partners's Intercept Pharmaceuticals, Inc. position peaked at $3.36M in Q2 2014.
175 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.